torsdag 17 september 2015
At Eli Lilly's website mentioned the two big sellers - Darvon & Darvocet - just on two occasions, to hide the pills fatal history
For some years ago, when there “were no problems at all “with Propoxyphene – Darvon, Darvocet – you could read a lot on Eli Lillys homepage about propoxyphene. Today when you search “Eli Lilly propoxyphene” on Google , you get 23 000 hits, if you Google “Lilly Darvocet” you get 46 000 hits.
But when you search for Propoxyphene on the homepage of Eli Lilly today you get 2 (two) hits, both referring to the Annual report, 2011 and 2012. http://bit.ly/1MaUguI
There you could read following
2011 – Eli Lilly Annual Report, and presented 2012 for the shareholders
“Along with several other manufacturers, we have been named as a defendant in approximately 165 cases in the U.S. involving approximately 755 claimants related to the analgesic Darvon and related formulations of Propoxyphene”.
2012 – Eli Lilly Annual Report, and presented 2013 for the shareholders
“Along with several other manufacturers, we have been named as a defendant in approximately 125 cases in the U.S. involving approximately 1,890 claimants related to the analgesic Darvon and related formulations of propoxyphene”
The Annual Reports for 2013 and 2014 do not have a single word about Propoxyphene or Darvon, Darvocet.
The shareholders have reason to be worried about the coming trails, we assure you it will be big problems for Eli Lilly and other involved companies.
It is about five years ago since Propoxyphene was banned in US (Nov 19th 2010) and the lawyers and judges have been discussing since then.
These Lawyers and judges have had complex legal discussions over these past five years. Apparently they cared not at all about the thousands of causes people affected, heart problems or who often have people become fatally poisoned.
Some others big trials where Eli Lilly also
The news-agency AP reported April 8, 2014:
Jury hits Takeda, Eli Lilly with $9-billion penalty
- U.S. jury ordered Japanese drugmaker Takeda Pharmaceutical Co. and its U.S. counterpart, Eli Lilly and Co, to pay $9 billion in punitive damages over a diabetes medicine linked to cancer. The drug companies said Tuesday they will "vigorously challenge" the decision.
- The U.S District Court in western Louisiana ordered a $6 billion penalty for Takeda and $3 billion for its business partner and co-defendant Eli Lilly. It also ordered $1.5 million in compensatory damages in favor of the plaintiff.
This process took some three years from beginning to end. The processes of Propoxyphene involving thousands of people thus have not even begun.
The question is when these trials can begin.